Trial Profile
Evaluation of Ranolazine on Skeletal Muscle Endpoints During Exercise In Subjects With Chronic Angina and Peripheral Arterial Disease.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 02 Sep 2015
Price :
$35
*
At a glance
- Drugs Ranolazine (Primary)
- Indications Angina pectoris; Peripheral arterial disorders
- Focus Pharmacodynamics
- 21 Jul 2011 Planned end date changed from 1 Jan 2009 to 1 Jun 2009 as reported by ClinicalTrials.gov.
- 21 Jul 2011 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
- 07 May 2008 New trial record.